News & Events
News & Events
[Gyeonggi Ilbo] Held hands for the drug discovery project targeting liver cancer
2016-07-06
.jpg)
Samjin Pharm and Insitut Pasteur Korea (IPK), with support from the Gyeonggi Provincial Government, [2016 IPK-Pharma co-research Project] will launch its first Drug Discovery project on liver cancer. Starting July 2016, Samjin Pharm’s compound optimization technology and IPK’s Phenomic screening technology will be used together to conduct basic research to discover drug candidates with the potential to be a first-in-class liver cancer drug. Despite liver cancer being the sixth most frequent cancer globally, and the second leading cause of cancer death, it has been difficult to develop targeted therapies. Research will take place over the next three years, but both Samjin Pharm and IPK have an expectation to continue collaborating on other drug discovery research projects in the coming years.
Dr. Haengran Seo, Group Leader of the Cancer Biology Research Laboratory at IPK says, “The early drug discovery process is an extremely important step in developing new drugs. IPK’s assay and screening technologies and methodology combined with IPK and Samjin Pharm’s current basic research will identify and optimize compounds that will lead to promising quality candidates for further late stage development.”
The collaboration between Samjin Pharm and IPK is supported by the Gyeonggi Provincial Government as part of the province’s mission to reinforce and invest in the research and development capabilities of Gyeonggi-based institutions. In 2016, five projects will be selected to co-research with IPK. The chosen institutions will have access to IPK’s award-winning screening platform and skilled research specialists as well as financial support from the Gyeonggi Provincial Government, generously matching the budget 1:1.
Source: Gyeonggi Ilbo (6 July, 2016)
Source: Gyeonggi Ilbo (6 July, 2016)